ALBANY, N.Y., Aug. 4, 2015 (GLOBE NEWSWIRE) -- AngioDynamics (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the launch of the BioFlo Midline catheter indicated for short-term intravenous therapies. The US Food and Drug Administration (FDA) granted 510(k) clearance for the BioFlo Midline catheter earlier this year.
The BioFlo Midline catheter often delivers the same medications, including a variety of antibiotics, as a peripheral intravenous catheter (PIV.) However, Midlines can provide access for up to thirty days while PIVs typically need to be replaced every couple of days, usually due to performance failure. Midline catheters are ideal for patients who may require more than five days of intravenous therapy.
“The BioFlo Midline catheter is a logical extension of the BioFlo product line, bringing the clinically relevant thrombus reduction properties to patients needing shorter term vascular access to deliver infusion therapies,” said Chuck Greiner, AngioDynamics’ Senior Vice President, Global Franchise Leader. “Its increased period of functionality improves patient satisfaction by lowering the number of needle sticks and interruptions to treatment. Similarly, it offers health care providers an expanded range of patient treatment options that help to increase staff efficiency and reduce the overall cost of care. We see BioFlo as the future of intravenous therapy delivery and our customers agree.”
The BioFlo Midline catheter with Endexo Technology is indicated for short-term or up to 30-days of peripheral access to the venous system for intravenous therapy, including but not limited to the administration of fluids, medications and nutrients; the sampling of blood and for power injections of contrast media.
“BioFlo product line sales grew at a double digit rate last fiscal year and the Midline’s launch, along with continued account wins and market penetration, position us for additional solid BioFlo growth this fiscal year,” added Joseph M. DeVivo, AngioDynamics’ President and Chief Executive Officer.
About BioFlo Technology
BioFlo Technology is not a coating or impregnated into the catheter. Instead, the Endexo technology polymer is added directly to the base polyurethane during the manufacturing process. Endexo technology is present throughout the catheter material, including the outer surface, inner surface and even the cut catheter tip. Endexo Technology is a proprietary polymer that is present throughout the catheter shaft material and remains present for the life of the catheter, providing long-term durability.
BioFlo Technology does not contain agents that may be associated with bacterial resistance, including antibiotics or antimicrobials. In addition, this catheter does not contain heparin, which may help minimize the complications associated with heparin use.
About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics’ diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at www.AngioDynamics.com.
Trademarks
AngioDynamics, the AngioDynamics logo and BioFlo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary. Endexo is a trademark and/or registered trademark of Interface Biologics, Inc.
Safe Harbor
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics’ expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, including Navilyst Medical and its products, R&D capabilities, infrastructure and employees as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2014. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
CONTACT: Company Contact: AngioDynamics Inc. Mark Frost, CFO (800) 772-6446 x1981 mfrost@AngioDynamics.com Investor Relations Contacts: EVC Group, Inc. Doug Sherk; Chris Daley (646) 445-4801 dsherk@evcgroup.com; cdaley@evcgroup.com Media Contact: EVC Group, Inc. Dave Schemelia (646) 201-5431 dave@evcgroup.com
Help employers find you! Check out all the jobs and post your resume.
